<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neurological disturbances frequently emerge in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>One hundred and twenty four patients (100 women, 24 men, mean age 37.5 +/- 11.3 years) with primary APS (PAPS), including 76 patients with <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon's syndrome</z:e> and positive antibodies to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> (aPL), have been studied </plain></SENT>
<SENT sid="2" pm="."><plain>A structure of neurological disturbances was as follows: ischemic lesions of cerebral blood flow (LCBF) which comprised <z:hpo ids='HP_0001297'>stroke</z:hpo> and transient LCBF (91%); <z:mp ids='MP_0005048'>thrombosis</z:mp> of brain venous sinuses (3%); <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> <z:hpo ids='HP_0001250'>seizures</z:hpo> (24%); <z:hpo ids='HP_0002315'>headache</z:hpo> (65%); <z:hpo ids='HP_0002072'>chorea</z:hpo> (15%); visual <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (9%); <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> (6%); multiple-<z:mp ids='MP_0000612'>sclerosis</z:mp>-like syndrome (10%); <z:hpo ids='HP_0003473'>myasthenia</z:hpo> syndrome (1%); syndrome of <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> of non-vascular genesis (1%) and <z:e sem="disease" ids="C0033975" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychotic disorders</z:e> (2%) </plain></SENT>
<SENT sid="3" pm="."><plain>84% patients had main systemic APS symptoms (fetal loss, <z:mp ids='MP_0005048'>thrombosis</z:mp>), which preceded neurological appearances in 78% cases </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients had aPL: aPL to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (aCL) and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> coagulant (LC) and/or aPL to <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> serine, <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> <z:chebi fb="1" ids="24848">inositol</z:chebi>, <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> <z:chebi fb="0" ids="16000,23981">ethanolamine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>In some patients, aCL titres ranged from positive to negative values and LC was not consistently detected </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, the presence of clinical symptoms of PAPS including neurological disturbances demands an investigation of different aPL types as well as a replicate study for immunological confirmation of PAPS </plain></SENT>
</text></document>